Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,873 shares of the medical research company’s stock after selling 367 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Charles River Laboratories International were worth $2,007,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Royal London Asset Management Ltd. increased its stake in shares of Charles River Laboratories International by 6.4% during the fourth quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company’s stock valued at $3,032,000 after acquiring an additional 991 shares during the period. Cibc World Markets Corp boosted its stake in Charles River Laboratories International by 16.1% during the 4th quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 1,124 shares in the last quarter. Hilton Capital Management LLC increased its position in shares of Charles River Laboratories International by 5.0% during the 4th quarter. Hilton Capital Management LLC now owns 8,038 shares of the medical research company’s stock valued at $1,484,000 after purchasing an additional 380 shares during the period. Impact Capital Partners LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth $422,000. Finally, Truvestments Capital LLC lifted its holdings in shares of Charles River Laboratories International by 6.4% in the fourth quarter. Truvestments Capital LLC now owns 2,562 shares of the medical research company’s stock valued at $473,000 after buying an additional 155 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Up 0.0 %

NYSE:CRL opened at $167.29 on Tuesday. The stock’s 50-day moving average is $165.66 and its two-hundred day moving average is $183.49. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market cap of $8.55 billion, a PE ratio of 1,115.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $273.57.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the company earned $2.46 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CRL. JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Barclays reduced their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Robert W. Baird cut their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).